Gsk (GSK) Accounts Payables (2009 - 2026)
Gsk (GSK) posted quarterly Accounts Payables of -$19.2 billion for Q2 2026, up 2.67% year-over-year from -$18.7 billion in Q2 2025, and little changed quarter-over-quarter from -$19.3 billion in Q1 2026.
Gsk (GSK) Accounts Payables (2009 - 2026) Analysis & Trends
Gsk's Accounts Payables history runs 18 years deep, the most recent figure standing at -$19.2 billion for Q2 2026.
- In Q2 2026, Accounts Payables rose 2.67% year-over-year to -$19.2 billion; the TTM figure through Jun 2026 stood at -$19.2 billion (up 2.67% YoY), while the FY2025 annual figure was -$20.3 billion, down 203.46% from the prior year.
- Accounts Payables for Q2 2026 stood at -$19.2 billion, roughly flat from -$19.3 billion in the prior quarter.
- The five-year high for Accounts Payables was $19.7 billion in Q4 2024, with the low at -$21.2 billion in Q3 2025.
- The 5-year median for Accounts Payables is -$18.7 billion (2022), against an average of -$11.8 billion.
- The sharpest annual moves came in 2022 and 2023: Accounts Payables surged 79.07% in 2022, then sank 311.35% in 2023.
- Gsk's Accounts Payables stood at $19.1 billion in 2022, then increased by 3.09% to $19.7 billion in 2023, then advanced by 0.09% to $19.7 billion in 2024, then tumbled by 203.95% to -$20.5 billion in 2025, then rose by 5.95% to -$19.2 billion in 2026.
- Business Quant data shows GSK's Accounts Payables at -$19.2 billion in Q2 2026, -$19.3 billion in Q1 2026, and -$20.5 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 9.22 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 33.30 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 3.83 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 4.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 22.89 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.87 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 674.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 4.58 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -19.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 8.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.24 Bn |
| Mar 31, 2026 | -19.33 Bn |
| Dec 31, 2025 | -20.46 Bn |
| Sep 30, 2025 | -21.15 Bn |
| Jun 30, 2025 | -19.77 Bn |
| Mar 31, 2025 | -19.08 Bn |
| Dec 31, 2024 | 19.68 Bn |
| Sep 30, 2024 | -18.68 Bn |
| Jun 30, 2024 | -17.98 Bn |
| Mar 31, 2024 | -18.55 Bn |
| Dec 31, 2023 | 19.66 Bn |
| Sep 30, 2023 | -19.74 Bn |
| Jun 30, 2023 | -17.46 Bn |
| Mar 31, 2023 | -17.34 Bn |
| Dec 31, 2022 | 19.08 Bn |
| Sep 30, 2022 | -18.99 Bn |
| Jun 30, 2022 | -18.65 Bn |
| Mar 31, 2022 | -4.22 Bn |
| Dec 31, 2021 | 23.66 Bn |
| Sep 30, 2021 | -21.00 Bn |